Is Tamiflu worth it?

  Research published in the British Medical Journal says there is no public evidence that Tamiflu reduces complications associated with influenza. Researchers attempting to review data about the Roche produced drug — dubbed “our best line of defence” against swine flu by the British health secretary — found the Swiss laboratory wouldn’t permit public access ...

575794_091208_tamiflu22.jpg
575794_091208_tamiflu22.jpg

 

Research published in the British Medical Journal says there is no public evidence that Tamiflu reduces complications associated with influenza. Researchers attempting to review data about the Roche produced drug -- dubbed "our best line of defence" against swine flu by the British health secretary -- found the Swiss laboratory wouldn't permit public access to the studies on the drugs.

Tamiflu might shorten influenza suffering by a day or so they said, based on information in the public domain, but it's not clear that chances of serious complications, like pneumonia, would be affected by Tamiflu. Such meager results mean it might not be worth confronting the side-effects, which include: "insomnia, nausea, bad dreams, abdominal pain, headache and a rare neuropsychiatric disease that caused some users to attempt to harm themselves."

 

Research published in the British Medical Journal says there is no public evidence that Tamiflu reduces complications associated with influenza. Researchers attempting to review data about the Roche produced drug — dubbed “our best line of defence” against swine flu by the British health secretary — found the Swiss laboratory wouldn’t permit public access to the studies on the drugs.

Tamiflu might shorten influenza suffering by a day or so they said, based on information in the public domain, but it’s not clear that chances of serious complications, like pneumonia, would be affected by Tamiflu. Such meager results mean it might not be worth confronting the side-effects, which include: “insomnia, nausea, bad dreams, abdominal pain, headache and a rare neuropsychiatric disease that caused some users to attempt to harm themselves.”

This is understandably a problem for the governments around the world who have stockpiled huge quantities of the drug to prescribe for H1N1, contributing to Roche’s estimated $2.65 billion in revenues this year from Tamiflu. In a very entertaining, but not too enlightening analogy, a Brit scientist tried to explain the situation policy makers now find themselves in when deciding to use the drug:

But I suppose that once you’ve gone and bought lots of doses, then it’s a bit like the situation with gun control in the US. If you have a gun in the house, it is much easier to use it. But it does not mean it’s the right thing to do.”

ANTONIO SCORZA/AFP/Getty Images

Jordana Timerman is a researcher at Foreign Policy.

More from Foreign Policy

An illustration shows George Kennan, the father of Cold War containment strategy.
An illustration shows George Kennan, the father of Cold War containment strategy.

Is Cold War Inevitable?

A new biography of George Kennan, the father of containment, raises questions about whether the old Cold War—and the emerging one with China—could have been avoided.

U.S. President Joe Biden speaks on the DISCLOSE Act.
U.S. President Joe Biden speaks on the DISCLOSE Act.

So You Want to Buy an Ambassadorship

The United States is the only Western government that routinely rewards mega-donors with top diplomatic posts.

Chinese President Xi jinping  toasts the guests during a banquet marking the 70th anniversary of the founding of the People's Republic of China on September 30, 2019 in Beijing, China.
Chinese President Xi jinping toasts the guests during a banquet marking the 70th anniversary of the founding of the People's Republic of China on September 30, 2019 in Beijing, China.

Can China Pull Off Its Charm Offensive?

Why Beijing’s foreign-policy reset will—or won’t—work out.

Turkish Defense Minister Hulusi Akar chairs a meeting in Ankara, Turkey on Nov. 21, 2022.
Turkish Defense Minister Hulusi Akar chairs a meeting in Ankara, Turkey on Nov. 21, 2022.

Turkey’s Problem Isn’t Sweden. It’s the United States.

Erdogan has focused on Stockholm’s stance toward Kurdish exile groups, but Ankara’s real demand is the end of U.S. support for Kurds in Syria.